Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis.
article
OA: closed
CC0
⤵ 15 in-corpus citations
AI-generated summary
Danazol and leuprorelin acetate treatments both reduced serum CA-125 levels in women with endometriosis, with danazol showing a more sustained effect post-treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To investigate the effects of danazol and leuprorelin acetate on CA-125 levels during treatment for endometriosis. PATIENTS AND METHODS: Fifty women with laparoscopically diagnosed and treated endometriosis, and 50 women without pelvic disease as a control group. Following surgical treatment, 35 women with endometriosis were divided into two groups. The first group (20 women) received 200 mg danazol three times daily for 6 months; the second group (15 women) received 3.75 mg leuprorelin acetate depot every 28 days for 6 months. Serum CA-125 levels were measured before medical treatment, during the last 15 days of the 6-month treatment course, and 3 months after treatment. RESULTS: Serum CA-125 levels were significantly higher in women with endometriosis than in women in the control group. Before treatment, CA-125 levels in patients with stage III/IV endometriosis were significantly higher than those in stage I/II endometriosis. Six months of danazol or leuprorelin acetate depot treatment decreased serum CA-125 levels. Three months after stopping danazol, CA-125 levels remained significantly lower than pretreatment levels. On the other hand, 3 months after stopping leuprorelin acetate, CA-125 levels returned to pretreatment levels. CONCLUSIONS: (a) Danazol and leuprorelin acetate are equally effective in the treatment of endometriosis. (b) Moreover, the results support the view that the determination of CA-125 levels may assist in evaluating progress of endometriosis treatment.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (15)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Blood biomarkers for the non-invasive diagnosis of endometriosis 2016
- Kuntai Capsule Inhibited Endometriosis via Inducing Apoptosis in a Rat Model 2016
- Endometriosis and possible inflammation markers 2015
- Serum Markers for the Noninvasive Diagnosis of Endometriosis 2015
- Theranekron for treatment of endometriosis in a rat model compared with medroxyprogesterone acetate and leuprolide acetate 2013
- ACUPUNCTURE IMPROVES THE EFFECTS OF CHINESE HERBAL MEDICINE IN TREATING ENDOMETRIOSIS MODEL RATS 2013
- Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment 2013
- Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women 2012
- Semi-invasive Diagnosis of Endometriosis Doctoral Thesis 2010
- Peripheral biomarkers of endometriosis: a systematic review 2010
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Effect of French maritime pine bark extract on endometriosis as compared with leuprorelin acetate. 2007
- Efficacy of levamisole on experimental endometriosis 2007
- The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis 2006
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:12:32.173627+00:00
License: CC0
· commercial use OK